Long-term Efficacy and Safety of Satralizumab▼ in Adults with AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the phase 3 SAkura studies
The long-term efficacy and safety of satralizumab▼ was assessed in adults with AQP4-IgG seropositive NMOSD from the SAkuraSky and SAkuraStar studies. The efficacy of satralizumab ▼(± IST) was sustained over more than 3.5 years; high proportions of patients remained free from relapse, severe relapse, or worsening disease. Additionally, the safety profile of satralizumab▼ (± IST) was sustained with up to 7 years of follow-up, with no new safety concerns.